Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Should You Buy?

Key Points

• Dianthus Therapeutics hit a new 52-week high of $93 and was last trading near $91.50, up about 4.8% on the day, valuing the company at roughly $4.19 billion.
• Analysts show a consensus Buy rating with an average price target of $115.55 (targets range up to $130 and include multiple recent upgrades, though one firm rates it a sell).
• The company reported a quarterly EPS miss (−$1.43 vs. −$0.97) with deeply negative margins and ROE, and insiders have sold about 323,021 shares (~$26.6M) in the past three months, including CEO Marino Garcia's ~$10M sale.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $93.00 and last traded at $91.5040, with a volume of 8827 shares traded. The stock had previously closed at $90.00.

Analyst Ratings Changes

Several research firms have weighed in on DNTH. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 9th. William Blair reissued an "outperform" rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. Finally, Wolfe Research began coverage on shares of Dianthus Therapeutics in a research report on Thursday, April 9th. They issued an "outperform" rating and a $98.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $115.55.

Dianthus Therapeutics Trading Up 4.8%

The firm's 50-day simple moving average is $68.20 and its two-hundred day simple moving average is $50.26. The company has a market cap of $4.19 billion, a PE ratio of -23.00 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 122,918 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ryan Savitz sold 8,224 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total transaction of $738,844.16. Following the transaction, the executive vice president directly owned 8,224 shares of the company's stock, valued at approximately $738,844.16. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,021 shares of company stock worth $26,564,008 over the last three months. 8.15% of the stock is owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $43,000. Seven Fleet Capital Management LP purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $604,000. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 125.9% during the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company's stock worth $4,182,000 after acquiring an additional 56,560 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $550,000. Finally, Voloridge Investment Management LLC grew its position in shares of Dianthus Therapeutics by 80.5% during the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company's stock worth $1,627,000 after acquiring an additional 17,612 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.